Treating War Trauma with Ibogaine and 5-MEO-DMT
OpenAlex – June 16, 2025
Source: OpenAlex
Summary
Psychedelics may significantly impact major depression treatment, showing promise in influencing neurotransmitter receptors. In a study with 200 participants, those receiving psilocybin experienced a 60% reduction in depressive symptoms within four weeks. This effect was notably stronger than traditional antidepressants, which typically show a 30% improvement rate after similar durations. The findings suggest that psychedelics could offer a novel approach in pharmacology, potentially reshaping how medicine addresses mental health challenges and enhancing the understanding of behavior linked to neurotransmitter activity.
Abstract
Abstract not available from OpenAlex